Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ELAN

ELAN - Elanco Animal Health Inc Stock Price, Fair Value and News

$24.12-0.50 (-2.03%)
Market Closed

30/100

ELAN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

30/100

ELAN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$19.52

Target 3M

$22.55

Target 6M

$20.81

ELAN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELAN Price Action

Last 7 days

-0.7%

Last 30 days

6.5%

Last 90 days

6.9%

Trailing 12 Months

98.2%

ELAN RSI Chart

ELAN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ELAN Valuation

Market Cap

12.0B

Price/Earnings (Trailing)

332.9

Price/Sales (Trailing)

2.61

EV/EBITDA

23.61

Price/Free Cashflow

32.57

ELAN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$19.52

Target 3M

$22.55

Target 6M

$20.81

ELAN Fundamentals

ELAN Revenue

Revenue (TTM)

4.6B

Rev. Growth (Yr)

10.39%

Rev. Growth (Qtr)

-8.38%

ELAN Earnings

Earnings (TTM)

36.0M

Earnings Growth (Yr)

-109.34%

Earnings Growth (Qtr)

-409.09%

ELAN Profitability

EBT Margin

-0.35%

Return on Equity

0.53%

Return on Assets

0.27%

Free Cashflow Yield

3.07%

ELAN Investor Care

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

0.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.4B4.5B4.6B0
20244.4B4.5B4.5B4.4B
20234.4B4.3B4.4B4.4B
20224.7B4.6B4.5B4.4B
20213.9B4.6B4.8B4.8B
20203.0B2.8B2.9B3.3B
20193.1B3.1B3.1B3.1B
20182.9B3.0B3.0B3.1B
20172.9B2.9B2.9B2.9B
20160002.9B
20150002.9B
Get all data in R, Python etc through our Historical Stock Data APIs

About Elanco Animal Health Inc

ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
 CEO
 WEBSITEelanco.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES9000

Elanco Animal Health Inc Frequently Asked Questions

ELAN is the stock ticker symbol of Elanco Animal Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Elanco Animal Health Inc is 11.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ELAN's fair value in chart for subscribers.

The fair value guage provides a quick view whether ELAN is over valued or under valued. Whether Elanco Animal Health Inc is cheap or expensive depends on the assumptions which impact Elanco Animal Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELAN.

As of Wed Jan 28 2026, ELAN's PE ratio (Price to Earnings) is 332.9 and Price to Sales (PS) ratio is 2.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELAN PE ratio will change depending on the future growth rate expectations of investors.